{"id":110868,"date":"2025-01-22T16:04:07","date_gmt":"2025-01-22T12:04:07","guid":{"rendered":"https:\/\/noortrends.ae\/en\/?p=110868"},"modified":"2025-01-22T16:04:11","modified_gmt":"2025-01-22T12:04:11","slug":"johnson-johnson-posts-strong-q4-results-beats-estimates-on-robust-cancer-drug-demand","status":"publish","type":"post","link":"https:\/\/noortrends.ae\/en\/johnson-johnson-posts-strong-q4-results-beats-estimates-on-robust-cancer-drug-demand\/01\/22\/market-updates\/","title":{"rendered":"Johnson &amp; Johnson Posts Strong Q4 Results, Beats Estimates on Robust Cancer Drug Demand"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p>Johnson &amp; Johnson (NYSE:JNJ) reported fourth-quarter earnings and sales that exceeded analysts\u2019 expectations, driven by strong demand for its cancer treatments and contributions from its recent acquisition of Shockwave Medical.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Q4 Highlights<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue:<\/strong> $22.52 billion, a 5.3% year-over-year increase.<\/li>\n\n\n\n<li><strong>Adjusted EPS:<\/strong> $2.04 per share, down 11% YoY but above analysts&#8217; expectations of $2.01.<\/li>\n\n\n\n<li><strong>Cancer Drug Sales:<\/strong> Up 19%, led by the multiple myeloma treatment <strong>Darzalex<\/strong>, which saw a nearly 21% surge to over $3 billion.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Key Factors Behind the Performance<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Cancer Treatments Driving Growth:<\/strong>\n<ul class=\"wp-block-list\">\n<li>The oncology portfolio continued to perform strongly, particularly with <strong>Darzalex<\/strong>, which remains a major revenue driver.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Shockwave Medical Acquisition:<\/strong>\n<ul class=\"wp-block-list\">\n<li>The $13.1 billion acquisition of <strong>Shockwave Medical<\/strong> contributed $258 million in quarterly sales. CFO Joe Wolk noted the deal significantly bolstered the company\u2019s top line.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Medical Technology and Innovative Medicine Units:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Growth in these divisions helped counteract headwinds in other areas.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Stelara Sales Decline:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Sales of <strong>Stelara<\/strong>, a treatment for psoriasis, dropped 14.7%, impacted by the launch of biosimilar competitors in several markets. The downward pressure is expected to continue with additional biosimilars entering the U.S. market.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2025 Outlook<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Year Revenue Guidance:<\/strong> $90.9 billion to $91.7 billion.<\/li>\n\n\n\n<li><strong>Adjusted EPS Guidance:<\/strong> $10.75 to $10.95.\n<ul class=\"wp-block-list\">\n<li>Both forecasts are above market expectations, reflecting management\u2019s confidence in sustained growth.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Earnings Impact<\/strong><\/h3>\n\n\n\n<p>The adjusted earnings figure included a <strong>$0.22 impairment charge<\/strong> related to J&amp;J\u2019s acquisition of V-Wave, a medical device manufacturer. Despite this one-time cost, the company delivered results that surpassed projections.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Strategic Outlook<\/strong><\/h3>\n\n\n\n<p>Johnson &amp; Johnson&#8217;s focus on high-growth therapeutic areas like oncology and investments in medical technology is paying off. While biosimilar competition poses challenges, the company&#8217;s diversified portfolio and strategic acquisitions position it well for continued growth.<\/p>\n\n\n\n<p>Investors will be closely watching the company\u2019s ability to manage competition and expand its market share in key therapeutic segments in 2025.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (NYSE:JNJ) reported fourth-quarter earnings and sales that exceeded analysts\u2019 expectations, driven by strong demand for its cancer treatments and contributions from its recent acquisition of Shockwave Medical. Q4 Highlights Revenue: $22.52 billion, a 5.3% year-over-year increase. Adjusted EPS: $2.04 per share, down 11% YoY but above analysts&#8217; expectations of $2.01. Cancer Drug &hellip;<\/p>\n","protected":false},"author":9,"featured_media":44351,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39,36],"tags":[7113,7825],"class_list":["post-110868","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-global-stock-markets","category-market-updates","tag-earnings","tag-johnson-johnson"],"_links":{"self":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/110868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/comments?post=110868"}],"version-history":[{"count":1,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/110868\/revisions"}],"predecessor-version":[{"id":110869,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/110868\/revisions\/110869"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/media\/44351"}],"wp:attachment":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/media?parent=110868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/categories?post=110868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/tags?post=110868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}